Financialsexperimental
Compass Therapeutics, Inc. (CMPX). Every figure is as filed in the company's 10-Q and 10-K reports. Quarters a filing does not report on their own are worked out from its year-to-date figures and marked *.
USD in thousands · shares in thousands · per-share amounts in USD
| Income Statement | Q2 FY26 30 Jun 2026 | Q1 FY26 31 Mar 2026 | Q4 FY25 31 Dec 2025 | Q3 FY25 30 Sept 2025 | Q2 FY25 30 Jun 2025 | Q1 FY25 31 Mar 2025 | Q4 FY24 31 Dec 2024 | Q3 FY24 30 Sept 2024 | Q2 FY24 30 Jun 2024 | Q1 FY24 31 Mar 2024 | Q4 FY23 31 Dec 2023 | Q3 FY23 30 Sept 2023 | Q2 FY23 30 Jun 2023 | Q1 FY23 31 Mar 2023 | Q4 FY22 31 Dec 2022 | Q3 FY22 30 Sept 2022 | Q2 FY22 30 Jun 2022 | Q1 FY22 31 Mar 2022 | Q4 FY21 31 Dec 2021 | Q3 FY21 30 Sept 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Licensing revenue | 0* | 0 | 0 | 0* | 0 | 850 | ||||||||||||||
| Research and development | 19,576 | 13,390 | 13,672* | 12,826 | 16,415 | 13,054 | 13,038* | 8,612 | 11,174 | 9,522 | 12,426* | 8,831 | 10,223 | 6,638 | 9,928* | 9,791 | 5,862 | 4,415 | 9,574* | 3,154 |
| General and administrative | 7,403 | 6,909 | 4,318* | 2,991 | 4,651 | 4,912 | 3,536* | 3,627 | 4,721 | 3,248 | 2,967* | 3,095 | 3,114 | 3,073 | 2,960* | 2,807 | 3,125 | 2,767 | 3,427* | 2,700 |
| Total operating expenses | 26,979 | 20,299 | 17,990* | 15,817 | 21,066 | 17,966 | 16,574* | 12,239 | 15,895 | 12,770 | 15,393* | 11,926 | 13,337 | 9,711 | 12,888* | 12,598 | 8,987 | 7,182 | 13,001* | 5,854 |
| In-process R&D | 0* | 0 | 0 | 0* | 0 | |||||||||||||||
| Loss from operations | -26,979 | -20,299 | -17,990* | -15,817 | -21,066 | -17,966 | -16,574* | -12,239 | -15,045 | -12,770 | -15,393* | -11,926 | -13,337 | -9,711 | -12,888* | -12,598 | -8,987 | -7,182 | -13,001* | -5,854 |
| Interest income | 1,825 | 1,982 | 2,274* | 1,558 | 1,185 | 1,333 | 1,541* | 1,758 | 1,969 | 1,983 | 1,978* | 1,962 | 2,059 | 1,874 | 1,294* | 623 | 493 | 20 | 7* | -121 |
| Loss before income tax expense | -16,633 | -13,076 | -10,787 | -13,415* | -9,964 | -11,278 | -7,837 | -11,594* | -11,975 | -8,494 | -7,162 | -12,994* | -5,975 | |||||||
| Net loss | -25,154 | -18,317 | -15,716* | -14,259 | -19,881 | -16,633 | -15,033* | -10,481 | -13,076 | -10,787 | -13,415* | -9,964 | -11,278 | -7,837 | -11,594* | -11,975 | -8,494 | -7,162 | -12,981* | -5,975 |
| Income tax expense | 0 | -0 | -0 | 0* | -0 | -0 | -0 | 0* | -0 | -0 | 0 | -13* | 0 | |||||||
| Net loss per share - basic and diluted (in dollars per share) | -0.13 | -0.1 | -0.08 | -0.14 | -0.12 | -0.08 | -0.1 | -0.08 | -0.08 | -0.09 | -0.06 | -0.12 | -0.08 | |||||||
| Basic and diluted weighted average shares outstanding (in shares) | 186,798 | 186,400 | 168,782 | 138,282 | 138,236 | 137,589 | 137,589 | 136,608 | 127,424 | 126,729 | 126,375 | 101,010 | 100,947 | |||||||
| Net loss per share - basic and diluted | -0.07 | -0.1 | ||||||||||||||||||
| Basic and diluted weighted average shares outstanding | 100,858 | 61,694 | ||||||||||||||||||
| Unrealized (loss) gain on marketable securities | -92 | -439 | 6* | 66 | 18 | -20 | -276* | 577 | -1 | -127 | 467* | 77 | -361 | 156 | 339* | -129 | -512 | |||
| Comprehensive loss | -25,246 | -18,756 | -15,710* | -14,193 | -19,863 | -16,653 | -15,309* | -9,904 | -13,077 | -10,914 | -12,948* | -9,887 | -11,639 | -7,681 | -11,255* | -12,104 | -9,006 |